News | Antiplatelet and Anticoagulation Therapies | May 06, 2016

Poor Warfarin Management Increases Kidney Failure Risk for Afib Patients

Study reveals patients who spend most time outside of optimal anticoagulation range at higher risk for long-term kidney health issues

warfarin, atrial fibrillation, kidney failure, HRS 2016

May 6, 2016 — Atrial fibrillation patients taking warfarin are at higher risk of developing kidney failure if anticoagulation levels are not properly managed, according to a new study from researchers at the Intermountain Medical Center Heart Institute.

Atrial fibrillation is the most common type of heart arrhythmia, which means the heart beats too slowly, too fast or in an irregular pattern. Between 2.7 and 6.1 million people in the United States are living with atrial fibrillation.

Among the most common treatments for atrial fibrillation is blood-thinning medication that prevents blood clots from forming, and thus reduces the risk of stroke or heart attack. Worldwide, warfarin is the most commonly used blood-thinning medication in patients with atrial fibrillation.

Levels of warfarin in the bloodstream are often erratic due to multiple interactions — drug-drug, drug-food and drug-supplement — that result in the need for frequent dose changes to maintain drug safety and efficacy.

A total of 2,753 patients with atrial fibrillation who were anticoagulated using warfarin and managed by Intermountain Healthcare Clinical Pharmacist Anticoagulation Services — who had a baseline creatinine level of less than 2.0 mg/dL or a glomerular filtration rate greater than 30 and serial renal function studies — were included in the study.

Patients were stratified into categories based on the amount of time their anticoagulation levels were determined to be in a therapeutic range. Researchers then examined kidney health in relation to the amount of time in or out of therapeutic range.

“Our study sought to examine the long-term kidney function of patients who were prescribed warfarin therapy as part of their atrial fibrillation treatment, and who were closely monitored by our Clinical Pharmacy Anticoagulation Service,” said T. Jared Bunch, M.D., director of heart rhythm research at Intermountain Medical Center Heart Institute in Salt Lake City.

Results of the study were presented during the Heart Rhythm Society’s (HRS) 37th Annual Scientific Sessions, May 4-7, 2016, in San Francisco.

If anticoagulation levels are too high, a patient is at risk of hemorrhaging. If the levels are too low, the patient is at risk for developing blood clots that may cause a heart attack or stroke.

These bleeding and clotting events can develop in any organ in the body. In this regard, precise use of anticoagulants in patients with atrial fibrillation is needed to minimize risk of organ injury.

“We learned several important lessons. First, anticoagulation is very important for the long-term kidney health of atrial fibrillation patients,” said Bunch. “Patients who had low times in therapeutic range — which is defined as the safe zone of anticoagulation — experienced significantly higher rates of kidney dysfunction and ultimately kidney failure. Second, all patients were at risk of developing kidney dysfunction, including those who started with healthy kidney function and those who started with moderate-severe kidney disease.”

Heart and kidney dysfunction are often correlated with each other, meaning if the function of either organ begins to decline, the other may be adversely affected, causing further organ damage. Research shows that approximately 18 to 20 percent of patients who have chronic kidney insufficiency have atrial fibrillation.

“Patients who use warfarin as part of their anticoagulation treatment for atrial fibrillation should have their anticoagulation levels closely monitored to ensure proper levels,” said Bunch. “Those who have erratic levels of warfarin despite close monitoring and care should consider other approaches such as newer anticoagulants that have more predictable blood effects, even if they have moderate kidney disease, and non drug-based methods to lower clot risk with atrial fibrillation.”

Other members of the Intermountain Medical Center Heart Institute team included: Heidi May, Ph.D.., MSPH; Tami Bair, RN; Victoria Jacobs; Brian G. Crandall, M.D.; J. Peter Weiss, M.D.; Jeffrey S. Osborn, M.D.; Charles Mallender, M.D.; John D. Day, M.D.; Jeffrey L. Anderson, M.D.,; Jeffrey L. Olson; Katie Johanning; Yenh Long; Scott M. Stevens, M.D.; and Scott C. Woller, M.D.

For more information:

Related Content

Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Overlay Init